Answers are grounded in this paper and cite their sources.
Background Cervical cancer is a critical global health challenge. An estimated 660,000 new cases and 350,000 deaths occurred worldwide in 2022, and about 94% of those deaths occurred in low- and middle-income countries, with sub-Saharan Africa carrying a disproportionate share of the burden. Rwanda has adapted the World Health Organization 90-70-90 elimination targets through its Mission 2027 strategy, which aims to vaccinate 90% of girls by age 15, screen 70% of women aged 30 to 49 years using HPV DNA based testing, and treat 90% of women diagnosed with precancerous lesions or invasive cervical cancer. As of October 2025, 30% of eligible women in Rwanda had been screened using HPV DNA based tests. This scoping review mapped the available evidence on cervical cancer screening uptake, and on the barriers and facilitators that shape it, among women aged 30 to 49 years in Rwanda. Methods The review was conducted and reported in accordance with the PRISMA-ScR guidance. PubMed, Scopus, Web of Science, Google Scholar and grey literature sources were searched for records published in English between January 2000 and May 2024, using strategies adapted to each platform. Sources were eligible if they addressed cervical cancer screening, drew on data collected in Rwanda, and reported barriers to or facilitators of screening uptake among women aged 30 to 49 years, or among a broader population from which findings relevant to this age band could be drawn. Two reviewers screened all titles, abstracts and full texts independently, and a third reviewer adjudicated disagreements. Methodological quality was appraised using standard quality assessment criteria for qualitative and for quantitative primary research. Findings were combined in a descriptive narrative synthesis organised by the level of the socio-ecological framework at which each factor operates. Results Twelve sources, reporting on eleven distinct participant samples, met the inclusion criteria. Higher household income and higher educational attainment were associated with a greater likelihood of having been screened, although these associations were drawn from small, single-site, facility-based samples recruited by non-probability sampling, with limited adjustment for confounding. They are cross-sectional associations rather than evidence of causal effects, and they cannot be generalised to women in Rwanda as a whole. In a multi-country analysis of Population-Based HIV Impact Assessment survey data, the absolute difference in screening probability between rural and urban women in Rwanda was 3.3 to 3.6% points across age groups, among the narrowest of the six countries compared. Barriers were reported at every level of the socio-ecological framework and included limited disease-specific knowledge, fear of the pelvic examination and anticipated stigma, insurance and cost-related constraints, long waiting times and travel distance, and shortages of trained and motivated providers. The facilitators reported most frequently were integration of screening with family planning and child health services, and high stated willingness to use HPV self-collection, which was measured as acceptability rather than as screening uptake or programme effectiveness. Conclusion The evidence base on cervical cancer screening among women aged 30 to 49 years in Rwanda is small, heterogeneous and largely facility based, and it therefore supports a mapping of barriers and facilitators rather than firm estimates of national screening uptake. Within these limits, low disease-specific knowledge, fear of the examination, and insurance and access constraints were the barriers reported most consistently, and service integration and HPV self-collection were the facilitators reported most consistently. Self-collection has so far been shown to be acceptable to women rather than effective in increasing uptake, and implementation research is required before national scale up. Nationally representative, age-disaggregated data on screening uptake are needed to monitor progress toward the 70% coverage target.
No takes yet. Share an insight, caveat, or question.
Sebera et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: